• Product name
    Anti-Androgen Receptor antibody
    See all Androgen Receptor primary antibodies
  • Description
    Goat polyclonal to Androgen Receptor
  • Host species
  • Tested applications
    Suitable for: WB, ELISA, IHC-Pmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Rat, Cow, Dog, Pig, Chimpanzee
  • Immunogen

    Synthetic peptide:


    , corresponding to N terminal amino acids 2-16 of Human Androgen Receptor

  • Positive control
    • Human Brain and Human Heart lysates.



Our Abpromise guarantee covers the use of ab19066 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 0.3 - 2 µg/ml. Detects a band of approximately 99 kDa (predicted molecular weight: 99 kDa).
ELISA 1/64000.
IHC-P Use a concentration of 2 - 3 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.


  • Function
    Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription factor activity is modulated by bound coactivator and corepressor proteins. Transcription activation is down-regulated by NR0B2. Activated, but not phosphorylated, by HIPK3 and ZIPK/DAPK3.
    Isoform 3 and isoform 4 lack the C-terminal ligand-binding domain and may therefore constitutively activate the transcription of a specific set of genes independently of steroid hormones.
  • Tissue specificity
    Isoform 2 is mainly expressed in heart and skeletal muscle (PubMed:15634333). Isoform 3 is expressed by basal and stromal cells of prostate (at protein level) (PubMed:19244107).
  • Involvement in disease
    Androgen insensitivity syndrome
    Spinal and bulbar muscular atrophy X-linked 1
    Defects in AR may play a role in metastatic prostate cancer. The mutated receptor stimulates prostate growth and metastases development despite of androgen ablation. This treatment can reduce primary and metastatic lesions probably by inducing apoptosis of tumor cells when they express the wild-type receptor.
    Androgen insensitivity, partial
  • Sequence similarities
    Belongs to the nuclear hormone receptor family. NR3 subfamily.
    Contains 1 nuclear receptor DNA-binding domain.
  • Domain
    Composed of three domains: a modulating N-terminal domain, a DNA-binding domain and a C-terminal ligand-binding domain. In the presence of bound steroid the ligand-binding domain interacts with the N-terminal modulating domain, and thereby activates AR transcription factor activity. Agonist binding is required for dimerization and binding to target DNA. The transcription factor activity of the complex formed by ligand-activated AR and DNA is modulated by interactions with coactivator and corepressor proteins. Interaction with RANBP9 is mediated by both the N-terminal domain and the DNA-binding domain. Interaction with EFCAB6/DJBP is mediated by the DNA-binding domain.
  • Post-translational
    Sumoylated on Lys-388 (major) and Lys-521. Ubiquitinated. Deubiquitinated by USP26. 'Lys-6' and 'Lys-27'-linked polyubiquitination by RNF6 modulates AR transcriptional activity and specificity.
    Phosphorylated in prostate cancer cells in response to several growth factors including EGF. Phosphorylation is induced by c-Src kinase (CSK). Tyr-535 is one of the major phosphorylation sites and an increase in phosphorylation and Src kinase activity is associated with prostate cancer progression. Phosphorylation by TNK2 enhances the DNA-binding and transcriptional activity and may be responsible for androgen-independent progression of prostate cancer. Phosphorylation at Ser-83 by CDK9 regulates AR promoter selectivity and cell growth. Phosphorylation by PAK6 leads to AR-mediated transcription inhibition.
    Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation is required for plasma membrane targeting and for rapid intracellular signaling via ERK and AKT kinases and cAMP generation.
  • Cellular localization
    Nucleus. Cytoplasm. Predominantly cytoplasmic in unligated form but translocates to the nucleus upon ligand-binding. Can also translocate to the nucleus in unligated form in the presence of RACK1.
  • Information by UniProt
  • Database links
  • Form
    There are 2 isoforms produced by alternative splicing. Isoform 1 is also known as: AR-B; isoform 2 is known as AR-A or variant AR45.
  • Alternative names
    • AIS antibody
    • ANDR_HUMAN antibody
    • Androgen nuclear receptor variant 2 antibody
    • Androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular atrophy; Kennedy disease) antibody
    • Androgen receptor antibody
    • androgen receptor splice variant 4b antibody
    • AR antibody
    • AR8 antibody
    • DHTR antibody
    • Dihydro testosterone receptor antibody
    • Dihydrotestosterone receptor (DHTR) antibody
    • Dihydrotestosterone receptor antibody
    • HUMARA antibody
    • HYSP1 antibody
    • KD antibody
    • Kennedy disease (KD) antibody
    • NR3C4 antibody
    • Nuclear receptor subfamily 3 group C member 4 (NR3C4) antibody
    • Nuclear receptor subfamily 3 group C member 4 antibody
    • SBMA antibody
    • SMAX1 antibody
    • Spinal and bulbar muscular atrophy (SBMA) antibody
    • Spinal and bulbar muscular atrophy antibody
    • Testicular Feminization (TFM) antibody
    • TFM antibody
    see all


  • ab19066 (2µg/ml) staining of paraffin embedded Human Prostate following steamed antigen retrieval with citrate buffer pH 6 and  AP-staining shows nuclear staining in the secretory cells of the gland.

  • ab19066 (0.3µg/ml) staining of Human Brain lysate (35µg protein in RIPA buffer) approx. 99kDa.  Primary incubation was 1 hour.  Detected by chemiluminescence.

    ab19066 (0.3µg/ml) staining of Human Brain lysate (35µg protein in RIPA buffer) approx. 99kDa. Primary incubation was 1 hour. Detected by chemiluminescence.
  • Immunohistochemical analysis of paraffin-embedded Human prostate tissue, staining Androgen Receptor with ab19066 at 2 µg/ml. Antigen retrieval was performed by heat mediation in a citrate buffer (pH 6).


This product has been referenced in:
  • Jin M  et al. The effects of neuromedin S on the hypothalamic-pituitary-testicular axis in male pigs in vitro. Gen Comp Endocrinol N/A:N/A (2019). Read more (PubMed: 30981702) »
  • Titus MA  et al. Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer. PLoS One 7:e30192 (2012). WB ; Human . Read more (PubMed: 22272301) »
See all 2 Publications for this product

Customer reviews and Q&As


BATCH NUMBER 380693 ORDER NUMBER 314211 DESCRIPTION OF THE PROBLEM No band at all. SAMPLE Protein extracted from LNCaP cells PRIMARY ANTIBODY Abcam/goat polyclonal to Androgen Receptor (ab19066)/1% non fat dry milk in TBST/ 1:250/ incubate overnight at 4°C/ wash with TBST once for 15 minutes and 4 times for 5 mins. DETECTION METHOD autorad film POSITIVE AND NEGATIVE CONTROLS USED None used. Did not have such controls at the time the experiment was run. ANTIBODY STORAGE CONDITIONS aliquoted and stored at -20°C SAMPLE PREPARATION RIPA buffer/EDTA-free protease inhibitor cocktail/heated sample for 5 minutes at 95°C AMOUNT OF PROTEIN LOADED Total protein extracted was about 100 ug/ml and 40 ul was loaded into gel. ELECTROPHORESIS/GEL CONDITIONS Reducing gel, 7.5% Tris-HCl ready gel TRANSFER AND BLOCKING CONDITIONS Transfer Buffer (25mM Tris, 192 mM glycine, 20% v/v methanol,pH 8.3)/ 100 volts for 120 mins. 5% non-fat dry milk was used as blocking buffer, incubation period was 1 hr. SECONDARY ANTIBODY Abcam/Rabbit polyclonal to Goat IgG - H&L (HRP) (ab6741)/1% non fat dry milk in TBST/ 1:5000/ incubate for 2 hrs at room temperature/ wash with TBST once for 15 minutes and 4 times for 5 mins. HOW MANY TIMES HAVE YOU TRIED THE APPLICATION? 7 HAVE YOU RUN A "NO PRIMARY" CONTROL? No DO YOU OBTAIN THE SAME RESULTS EVERY TIME? Yes WHAT STEPS HAVE YOU ALTERED? Protein concentration, primary antibody dilution (1:100 - 1:1000) and incubation time (1 hr at room temperature to overnight at 4°C),secondary antibody dilution (1:4000 - 1:7000) and incubation time( 1 - 2 hrs at room tempertature) and auto rad film exposure time (10 sec to 2 hrs) ADDITIONAL NOTES I have run western blot on protein extracted from LNCaP cells several time with no results. I do not get any bands at all. I have optimized what I believe are the critical stages of the process e.g. protein concentration, primary antibody dilution and incubation times, secondary antibody dilution and incubation times and the wash steps for each stage. As such, I am beginning to wonder whether there might be a problem with the antibody itself. Please advise. Also could you kindly send me a replacement that works? Thanks

Read More

Thank you for your protocol details, I am very sorry to hear you are experiencing problems with ab19066. I think your protocol is really good and your optimisation steps very detailed and thorough. I have noticed two points which may be the reasons why you are not seeing any bands currently: -the amount you are loading is only 4ug/lane according to my calculations. We recommend to load 20-40ug; I would recommend to increase the amount to 40ug. -the secondary antibody may be the problem: could you test the primary with another secondary antibody. We'll happily offer a replacement vial if the secondary antibody is at fault, under our 4 months Abpromise. I hope these suggestions will resolve the problem; if you still have problems when loading more antibody and the secondary antibody is not at fault please contact us again and we will arrange a replacement vial of ab19066.

Read More

For licensing inquiries, please contact partnerships@abcam.com

Sign up